The FDA on August 24, 2015 approved PROMACTA® for the treatment of thrombocytopenia in pediatric patients 1 year and older with chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP), who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. PROMACTA® oral suspension is a product of Novartis Pharmaceuticals Corporation.
Bottom Ad
Advertisement
Subscribe
